These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
677 related articles for article (PubMed ID: 21242363)
1. ACP Journal Club. Celecoxib reduced GI events more than diclofenac plus omeprazole in patients with osteoarthritis or rheumatoid arthritis. Gonzalez EB Ann Intern Med; 2011 Jan; 154(2):JC1-9. PubMed ID: 21242363 [No Abstract] [Full Text] [Related]
2. Efficacy and safety of celecoxib versus diclofenac and omeprazole in elderly arthritis patients: a subgroup analysis of the CONDOR trial. Kellner HL; Li C; Essex MN Curr Med Res Opin; 2012 Sep; 28(9):1537-45. PubMed ID: 22852870 [TBL] [Abstract][Full Text] [Related]
3. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. Chan FK; Hung LC; Suen BY; Wu JC; Lee KC; Leung VK; Hui AJ; To KF; Leung WK; Wong VW; Chung SC; Sung JJ N Engl J Med; 2002 Dec; 347(26):2104-10. PubMed ID: 12501222 [TBL] [Abstract][Full Text] [Related]
4. Celecoxib and Diclofenac Plus Omeprazole are Similarly Effective in the Treatment of Arthritis in Patients at High GI Risk in the CONDOR Trial. Kellner HL; Li C; Essex MN Open Rheumatol J; 2013; 7():96-100. PubMed ID: 24358067 [TBL] [Abstract][Full Text] [Related]
5. Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective. Bessette L; Risebrough N; Mittmann N; Roussy JP; Ho J; Zlateva G J Med Econ; 2009 Sep; 12(3):246-58. PubMed ID: 19743942 [TBL] [Abstract][Full Text] [Related]
6. Risk factors associated with a decrease ≥2 g/dL in haemoglobin and/or ≥10% haematocrit in osteoarthritis patients taking celecoxib or a nonselective NSAID plus a PPI in a large randomised controlled trial (CONDOR). Lanas A; Goldstein JL; Chan FK; Wilcox CM; Peura DA; Li C; Sands GH; Scheiman JM Aliment Pharmacol Ther; 2012 Sep; 36(5):485-92. PubMed ID: 22804104 [TBL] [Abstract][Full Text] [Related]
7. Incidence of gastroduodenal ulcers during treatment with celecoxib or diclofenac: pooled results from three 12-week trials in Chinese patients with osteoarthritis or rheumatoid arthritis. Cheung R; Cheng TT; Dong Y; Lin HY; Lai K; Lau CS; Feng H; Parsons B Int J Rheum Dis; 2010 May; 13(2):151-7. PubMed ID: 20536600 [TBL] [Abstract][Full Text] [Related]
8. Gastrointestinal tolerability of NSAIDs in elderly patients: a pooled analysis of 21 randomized clinical trials with celecoxib and nonselective NSAIDs. Mallen SR; Essex MN; Zhang R Curr Med Res Opin; 2011 Jul; 27(7):1359-66. PubMed ID: 21561397 [TBL] [Abstract][Full Text] [Related]
9. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis. Hochberg MC Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069 [TBL] [Abstract][Full Text] [Related]
10. ACP Journal Club. Adding omeprazole to clopidogrel reduced GI events and did not increase CV events. Chow CK Ann Intern Med; 2011 Mar; 154(6):JC3-7. PubMed ID: 21403070 [No Abstract] [Full Text] [Related]
11. Celecoxib in osteoarthritis and rheumatoid arthritis: new preparation. As disappointing as rofecoxib. Prescrire Int; 2001 Apr; 10(52):46-9. PubMed ID: 11718158 [TBL] [Abstract][Full Text] [Related]
12. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. Singh G; Fort JG; Goldstein JL; Levy RA; Hanrahan PS; Bello AE; Andrade-Ortega L; Wallemark C; Agrawal NM; Eisen GM; Stenson WF; Triadafilopoulos G; Am J Med; 2006 Mar; 119(3):255-66. PubMed ID: 16490472 [TBL] [Abstract][Full Text] [Related]
13. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis. Maetzel A; Krahn M; Naglie G Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781 [TBL] [Abstract][Full Text] [Related]
14. A randomized, multicentre, double-blind, parallel-group study to assess the adverse event-related discontinuation rate with celecoxib and diclofenac in elderly patients with osteoarthritis. Dahlberg LE; Holme I; Høye K; Ringertz B Scand J Rheumatol; 2009; 38(2):133-43. PubMed ID: 19165648 [TBL] [Abstract][Full Text] [Related]
15. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070 [TBL] [Abstract][Full Text] [Related]
16. Multicentre trial in people with arthritis finds increased risk of clinically significant gastrointestinal events with diclofenac plus omeprazole compared with celecoxib. Rostom A Evid Based Med; 2011 Aug; 16(4):110-1. PubMed ID: 21771819 [No Abstract] [Full Text] [Related]
17. Are rofecoxib and celecoxib safer NSAIDS? Drug Ther Bull; 2000 Nov; 38(11):81-6. PubMed ID: 11138599 [TBL] [Abstract][Full Text] [Related]
18. Impact of Celecoxib restrictions in medicare beneficiaries with arthritis. Louder AM; Joshi AV; Ball AT; Cappelleri JC; Deminski MC; Sanchez RJ Am J Manag Care; 2011; 17(7):503-12. PubMed ID: 21819170 [TBL] [Abstract][Full Text] [Related]
19. A novel composite endpoint to evaluate the gastrointestinal (GI) effects of nonsteroidal antiinflammatory drugs through the entire GI tract. Chan FK; Cryer B; Goldstein JL; Lanas A; Peura DA; Scheiman JM; Simon LS; Singh G; Stillman MJ; Wilcox CM; Berger MF; Breazna A; Dodge W J Rheumatol; 2010 Jan; 37(1):167-74. PubMed ID: 19884267 [TBL] [Abstract][Full Text] [Related]
20. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials. Soni P; Shell B; Cawkwell G; Li C; Ma H Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]